Wide Ranks

AGEN

Agenus Inc.

3.49

Top Statistics
Market Cap 82 M Forward PE -0.3532 Revenue Growth 3.30 %
Current Ratio 0.18 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -141.90 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.62 Enterprise / Revenue 0.8640 Price To Sales Trailing12 Months 0.5137
Profitability
Profit Margins -141.90 % Operating Margins -132.87 %
Balance Sheet
Total Cash 44 M Total Cash Per Share 1.91 Total Debt 81 M
Total Debt To Equity Current Ratio 0.18 Book Value Per Share -13.48
All Measures
Short Ratio 551.00 % Message Board Id finmb_409956 Fax 781 674 4200
Shares Short Prior Month 3 M City Lexington Uuid 66667c6c-8d93-375a-afa8-fd070a978392
Previous Close 3.38 First Trade Date Epoch Utc 950 M Book Value -13.48
Beta 1.39 Total Debt 81 M Volume 1 M
Last Split Date 1 B Fifty Two Week Low 2.50 Total Cash Per Share 1.91
Total Revenue 160 M Shares Short Previous Month Date 1 B Target Median Price 7.50
Audit Risk 4 Max Age 86400 Recommendation Mean 2.60
Sand P52 Week Change 0.3133 Operating Margins -132.87 % Target Mean Price 8.00
Net Income To Common -227856992 Short Percent Of Float 0.1125 Implied Shares Outstanding 23 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 809000
Average Volume10days 809000 Total Cash 44 M Next Fiscal Year End 1 B
Revenue Per Share 7.81 Held Percent Insiders 0.0125 Ebitda Margins -53.31 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 3.38 Target Low Price 6.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.25 Open 3.50
Free Cashflow -34503624 State MA Dividend Yield 0.00 %
Return On Assets -0.2195 Time Zone Short Name EST Board Risk 9
Trailing Eps -11.02 Day Low 3.48 Address1 3 Forbes Road
Shares Outstanding 23 M Compensation Risk 7 Price Hint 4
Target High Price 11.00 Website https://www.agenusbio.com 52 Week Change -0.7763
Average Volume 463915 Forward Eps -9.69 Recommendation Key hold
Compensation As Of Epoch Date 1 B Quick Ratio 16.60 % Last Split Factor 1:20
Regular Market Day High 4.06 Is_sp_500 False Profit Margins -141.90 %
Fifty Two Week High 19.69 Day High 4.06 Shares Short 2 M
Regular Market Open 3.50 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 0.8640 Revenue Growth 3.30 % Shares Percent Shares Out 0.1117
Operating Cashflow -170064992 Currency USD Time Zone Full Name America/New_York
Market Cap 82 M Is_nasdaq_100 False Zip 02421-7305
Quote Type EQUITY Industry Biotechnology Long Name Agenus Inc.
Overall Risk 8 Regular Market Day Low 3.48 Held Percent Institutions 0.3715
Current Price 3.49 Enterprise To Ebitda -1.62 Financial Currency USD
Current Ratio 0.18 Gross Margins -17.88 % Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country United States Float Shares 23 M
Two Hundred Day Average 9.06 Governance Epoch Date 1 B Ir Website http://www.agenusbio.com/investors/performance.shtml
Price To Sales Trailing12 Months 0.5137 Enterprise Value 138 M Forward PE -0.3532
Regular Market Volume 1 M Ebitda -85517000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.

The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies.

In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody.

The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks.

It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co.

, Ltd.

, Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.

Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.